Generative AI will significantly shorten the timeline for drug development

Artificial intelligence research, products, and impact across society.

Artificial intelligence applications across healthcare, covering clinical decision support, diagnostics, workflow automation, drug discovery, patient monitoring, safety risks, equity concerns, and regulation.

Accelerating scientific discovery using machine learning and AI methods.

On October 20, 2026 OpenAI acquired Orchestra Bio, a startup building AI agents that help pharmaceutical companies manage drug development, and said it would fold the startup into its Rosalind life sciences models and tools; financial terms were not disclosed.

Service category applying machine learning, generative chemistry, protein modeling, and biological data analysis to identify targets, design molecules, prioritize candidates, and accelerate pharmaceutical research.

Models that generate new content. Includes text, image, and audio generation.